Abbvie Inc.

  • Earnings Score
  • Safety Score
  • Market Cap $354.38B
  • PE 70
  • Debt $71.08B
  • Cash $7.26B
  • EV $418.21B
  • FCF $15.62B

Earnings

loading chart...

Sales & Net Margins

loading chart...
Earnings$5.08B
EBIT$13.82B
ROE84%
ROA10%
FCF$15.62B
Equity$6.07B
Growth Stability52%
PE69.75
PEG-20.63
PB58.37
P/FCF22.68
P/S6.38
Price/Cash0.02
Debt/Equity11.71
Debt/FCF4.55
Net Margins10%
Gross Margins67%
Op. Margins25%
Earnings CAGR4%
Sales Growth YoY4%
Sales Growth QoQ-0%
Sales CAGR13%
FCF CAGR17%
Equity CAGR11%
Earnings Stability0.09
Earnings Growth YoY-12%
Earnings Growth QoQ14%
Earnings CAGR 5Y-3%
Sales CAGR 5Y10%
FCF CAGR 5Y9%
Equity CAGR 5Y-14%
Earnings CAGR 3Y-2%
Sales CAGR 3Y-2%
FCF CAGR 3Y-8%
Equity CAGR 3Y-30%
Market Cap$354.38B
Revenue$55.53B
Dividend Yield3%
Payout Ratio217%
Assets$143.42B
Total Debt$71.08B
Cash$7.26B
Shares Outstanding1.77B
EV418.21B
Earnings Score7%
Safety Score47%
Working Capital-15.28B
Current Ratio0.65
Shares Growth 3y-0%
Equity Growth QoQ-11%
Equity Growth YoY-50%

Assets & ROA

loading chart...

Stockholders Equity & ROE

loading chart...
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.

SEC Filings

Direct access to Abbvie Inc. (ABBV) Annual Reports (10K) and Quarterly Reports (10Q) from the SEC website.

  • 2024
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2023
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31
  • 2022
    • 10-K Dec 31
    • 10-Q Sep 30
    • 10-Q Jun 30
    • 10-Q Mar 31

Sector Comparison

How does Abbvie Inc. compare to its competitors?

Loading chart...

Peter Lynch's Chart

This chart shows the current pricing of Abbvie Inc. compared to its past. The addition of the earnings trend line provides further insights into the company's earnings power.

CAGR 4%
Stability 9%
loading chart...

Abbvie Inc. Discounted Cash Flow

Fully customizable DCF calculator online for Abbvie Inc..

= $510B
012345678910TV
fcf$16B$18B$21B$25B$29B$34B$40B$47B$55B$64B$75B$748B
DCF$17B$18B$19B$20B$21B$23B$24B$26B$27B$29B$288B
Value$510B

Competitiveness and MOAT

High margins render the company resilient under dire circumstances, hence able to drive competitors out or acquire them. ROE and ROA measure the average flow generated by each invested dollar. Their marginal value is a forecast of future growth, and it is considered by Buffett and Munger the most important single indicator.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Net Margins9%23%23%19%17%24%10%20%20%9%10%
ROA-14%14%14%11%15%8%12%13%9%10%
ROE-130%128%104%-67%-96%35%74%68%46%84%

Safety and Stability

Being debt the number one cause of investment losses and company death, the ratio Debt/FCF is of utmost importance to guarantee safety. On the other hand the Graham’s stability measures the drawdown of earnings, hence indicating the reliability of the flow generated by the company.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023TTM
Debt over FCF-4.465.613.923.035.565.564.022.773.014.55
Debt over Equity8.377.937.947.25-4.58-8.697.135.733.896.3911.71
Growth Stability---100%100%100%73%100%100%52%52%

Growth

Growth can be dangerous when forecasting, simply projecting the current growth is in general wrong. A company passes through multiple phases, from being young and unprofitable, to the first periods of profitability and high growth, until it arrives at a period of regime with limited growth. Identifying in which phase the company is in may help forecasting.

Years12/201412/201512/201612/201712/201812/201912/202012/202112/202212/2023CAGR 5Y
Revenue YoY growth-15%12%10%16%2%38%23%3%-6%10%
Earnings YoY growth-190%15%-11%7%39%-42%152%3%-59%-3%
Equity YoY growth-126%18%10%-266%-3%-260%18%12%-40%-14%
FCF YoY growth-138%-6%44%36%-0%31%31%10%-9%9%